A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is an open-label, multicenter Phase 2 study evaluating BMS-986504 in participants with advanced and/or metastatic solid tumors that have MTAP deletion. The study includes a monotherapy component and a combination component in which BMS-986504 is given with other anti-cancer agents. The trial will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of BMS-986504 alone and in combination regimens.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony nowotwór w stadium zaawansowanym lub z przerzutami, z uszkodzonym genem MTAP.
- •Choroba postępująca mimo wcześniejszego leczenia, lub brak możliwości zastosowania innego leczenia.
- •Pacjent musi mieć widoczne zmiany nowotworowe do zmierzenia.
- •W dobrej ogólnej kondycji zdrowotnej (parametr ECOG 0 lub 1).
✗ Disqualifies
- •Nie można wcześniej przyjmować leków wpływających na PRMT5 lub MAT2A.
- •Brak aktywnego raka mózgu lub zapalenia opon mózgowych na tle nowotworowym (chyba że został skutecznie wyleczony).
- •Nie można mieć problemów z jelitami w ciągu ostatnich 6 miesięcy, które mogłyby wpływać na wchłanianie leków.
- •Zapewnione prawidłowe funkcjonowanie narządów (np. wątroby, nerek).
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 30, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (57)
Local Institution - 0096
San Francisco, United States
Local Institution - 0182
Aurora, United States
Local Institution - 0178
Atlanta, United States
Johns Hopkins Hospital
Baltimore, United States
Local Institution - 0124
Boston, United States
Local Institution - 0119
Ann Arbor, United States
Local Institution - 0129
Rochester, United States
Local Institution - 0174
Rochester, United States
Local Institution - 0181
Rochester, United States
Local Institution - 0142
Buffalo, United States
Local Institution - 0170
New York, United States
Local Institution - 0139
New York, United States
Local Institution - 0100
Durham, United States
Local Institution - 0085
Houston, United States
Local Institution - 0086
Seattle, United States
Local Institution - 0134
Madison, United States
Local Institution - 0148
Brussels, Belgium
Local Institution - 0114
Ghent, Belgium
Local Institution - 0051
Vancouver, Canada
Local Institution - 0021
Toronto, Canada
Local Institution - 0007
Toronto, Canada
Local Institution - 0155
Beijing, China
Local Institution - 0185
Chongqing, China
Local Institution - 0184
Guangzhou, China
Local Institution - 0152
Xinxiang, China
Shanghai GoBroad Cancer Hospital China Pharmaceutical University
Shanghai, China
Fudan University Shanghai Cancer Center
Shanghai, China
Local Institution - 0078
Dijon, France
Local Institution - 0075
Pierre-Bénite, France
Local Institution - 0116
Villejuif, France
Local Institution - 0074
Paris, France
Local Institution - 0081
Mainz, Germany
Local Institution - 0040
Hamburg, Germany
Local Institution - 0039
Heidelberg, Germany
Local Institution - 0061
Leipzig, Germany
Local Institution - 0049
München, Germany
Local Institution - 0047
Würzburg, Germany
Local Institution - 0150
Hksar, Hong Kong
Local Institution - 0063
Shatin, Hong Kong
Local Institution - 0080
Cork, Ireland
Local Institution - 0023
Dublin, Ireland
Local Institution - 0146
Dublin, Ireland
Local Institution - 0073
Siena, Italy
Local Institution - 0123
Bergamo, Italy
Local Institution - 0034
Milan, Italy
Local Institution - 0050
Naples, Italy
Local Institution - 0082
Perugia, Italy
National Cancer Center Hospital
Chuo-ku, Japan
Local Institution - 0171
Bergen, Norway
Local Institution - 0022
Oslo, Norway
Local Institution - 0004
Seoul, South Korea
Local Institution - 0058
Seoul, South Korea
Local Institution - 0052
Seoul, South Korea
Local Institution - 0068
Barcelona, Spain
Local Institution - 0071
Hospitalet, Spain
Local Institution - 0033
Madrid, Spain
Local Institution - 0069
Seville, Spain
Trial contact
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
First line of the email MUST contain NCT # and Site #.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/31/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.